Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
暂无分享,去创建一个
[1] A. Salama,et al. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review. , 2018, Blood transfusion = Trasfusione del sangue.
[2] F. Ferrara,et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers , 2018, American journal of hematology.
[3] Heather D. Huntsman,et al. Heterodimerization of TPO and IFNγ Impairs Human Hematopoietic Stem/Progenitor Cell Signaling and Survival in Chronic Inflammation , 2017 .
[4] M. Hernandez,et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres , 2017, European journal of haematology.
[5] D. Kaplan. Persistence of exhaustion in cured hep C. , 2017, Blood.
[6] I. Durieu,et al. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. , 2017, La Revue de medecine interne.
[7] S. Zuluaga,et al. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center , 2017, Annals of Hematology.
[8] D. Kaplan,et al. Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation , 2016, Haematologica.
[9] W. Vainchenker,et al. Eltrombopag, a potent stimulator of megakaryopoiesis , 2016, Haematologica.
[10] F. Roudot-thoraval,et al. Long-term complications of splenectomy in adult immune thrombocytopenia , 2016, Medicine.
[11] G. Salles,et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. , 2016, Blood.
[12] A. Cuker,et al. How I treat refractory immune thrombocytopenia. , 2016, Blood.
[13] J. Zehnder,et al. Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia , 2016, American journal of hematology.
[14] R. Cairoli,et al. Response loss and development of neutralizing antibodies during long‐term treatment with romiplostim in patients with immune thrombocytopenia: a case series , 2016, European journal of haematology.
[15] J. Bussel,et al. Randomized Double-Blind Study of Increasing Doses of Eltrombopag in Patients with Chronic ITP , 2015 .
[16] R. Hanada,et al. Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. , 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[17] M. Carroll,et al. Eltrombopag Modulates Reactive Oxygen Species and Decreases Acute Myeloid Leukemia Cell Survival , 2015, PloS one.
[18] A. Waage,et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[19] J. González-Porras,et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia , 2015, British journal of haematology.
[20] D. Kuter,et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim , 2015, International Journal of Hematology.
[21] Ronan Desmond,et al. Eltrombopag in aplastic anemia. , 2015, Seminars in hematology.
[22] F. Rodeghiero,et al. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. , 2015, Seminars in hematology.
[23] P. Mazza,et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP) , 2015, Annals of Hematology.
[24] N. Vianelli,et al. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis , 2015, Annals of Hematology.
[25] B. Psaila,et al. Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators , 2014 .
[26] R. Elstrom,et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration , 2014, Haematologica.
[27] M. Giovannini,et al. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. , 2014, Blood transfusion = Trasfusione del sangue.
[28] A. Piccin,et al. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. , 2014, Blood transfusion = Trasfusione del sangue.
[29] G. Tagariello,et al. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim. , 2014, Blood transfusion = Trasfusione del sangue.
[30] Masami Takeuchi,et al. Safety and efficacy of romiplostim in patients with eltrombopag‐resistant or ‐intolerant immune thrombocytopenia , 2013, British journal of haematology.
[31] D. Kuter. The biology of thrombopoietin and thrombopoietin receptor agonists , 2013, International Journal of Hematology.
[32] A. Savoia,et al. Inherited thrombocytopenias frequently diagnosed in adults , 2013, Journal of thrombosis and haemostasis : JTH.
[33] F. Roudot-thoraval,et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia , 2013, Haematologica.
[34] P. Musto,et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. , 2013, Blood.
[35] A. Tichelli,et al. Severe cutaneous toxicity related to Eltrombopag , 2013, British journal of haematology.
[36] T. Nakazato,et al. Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim , 2013, International Journal of Hematology.
[37] T. Aoki,et al. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations , 2012, Journal of clinical pharmacy and therapeutics.
[38] J. Bussel,et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. , 2012, Blood.
[39] C. Mitsiades,et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. , 2012, Blood.
[40] K. Shinohara,et al. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim. , 2012, Internal medicine.
[41] M. Crowther,et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.
[42] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[43] D. Kuter. New thrombopoietic growth factors. , 2007, Blood.
[44] J. Nichol. Endogenous TPO (eTPO) levels in health and disease: Possible clues for therapeutic intervention , 1998, Stem cells.